Details for Patent: 9,790,208

✉ Email this page to a colleague

Which drugs does patent 9,790,208 protect, and when does it expire?

Patent 9,790,208 protects QUVIVIQ and is included in one NDA.

This patent has thirty-seven patent family members in thirty-two countries.

Summary for Patent: 9,790,208

Title:	Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-- yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Abstract:	The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-- yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
Inventor(s):	Boss; Christoph (Allschwil, CH), Brotschi; Christine (Allschwil, CH), Gude; Markus (Allschwil, CH), Heidmann; Bibia (Allschwil, CH), Sifferlen; Thierry (Allschwil, CH), Von Raumer; Markus (Allschwil, CH), Williams; Jodi T. (Allschwil, CH)
Assignee:	IDORSIA PHARMACEUTICALS LTD (Allschwil, CH)
Application Number:	15/101,832
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,790,208

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-002	Apr 7, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,790,208

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/IB2013/060595	Dec 3, 2013

PCT Information
PCT Filed	December 02, 2014	PCT Application Number:	PCT/IB2014/066509
PCT Publication Date:	June 11, 2015	PCT Publication Number:	WO2015/083071

International Family Members for US Patent 9,790,208

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014358743	⤷ Sign Up
Brazil	112016012625	⤷ Sign Up
Canada	2929720	⤷ Sign Up
Chile	2016001348	⤷ Sign Up
China	105793258	⤷ Sign Up
Cyprus	1119687	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.